Novel Drug Review of Select
Neurologic Drugs Approved in 2019
Each year, the Food and Drug Administration (FDA) releases a comprehensive list of all novel drugs approved throughout the year. The FDA’s Center for Drug Evaluation and Research strives to approve new drugs to fill the gaps in healthcare of unmet needs of patients. This article focuses on select novel drugs approved in 2019, specifically for neurologic conditions. Drugs included are Cyplyta, a second-generation antipsychotic used in the maintenance of schizophrenia; Ubrelvy, a CGRP antagonist used for acute migraine attacks; Zulresso, the first drug treatment indicated for postpartum depression; and Wakix, the first noncontrolled treatment for excessive daytime sleepiness in narcoleptic patients.